SPRY Furnishes Q2 Results and Posts Revised Investor Deck; Exhibits Included

Rhea-AI Filing Summary

ARS Pharmaceuticals, Inc. announced its financial results for the quarter ended June 30, 2025 via a press release attached to this Form 8-K as Exhibit 99.1. The company states that the press release is furnished and expressly not "filed" for purposes of the Exchange Act, and therefore is not incorporated by reference into other filings. The filing also confirms that ARS is an emerging growth company and that its common stock trades on The Nasdaq Stock Market under the symbol SPRY.

The company also updated its corporate investor presentation, which is available on the company website and is attached as Exhibit 99.2. The 8-K repeats that the presentation is furnished and not deemed filed, and lists the exhibits including the Interactive Data File Cover Page as Exhibit 104.

Positive

• Press release announcing Q2 results attached as Exhibit 99.1, making the company's quarterly disclosure available to investors
• Updated investor presentation attached as Exhibit 99.2 and posted on the company website
• Clear legal treatment noted: exhibits are furnished and not deemed filed, clarifying incorporation status
• Company trades as SPRY on The Nasdaq Stock Market; the filing reiterates the ticker and exchange

Negative

• None.

Insights

Securities Analyst

TL;DR: Routine 8-K furnishing quarterly results and an updated investor deck; no financial details are presented here.

The filing notifies investors that ARS furnished a press release with Q2 results (quarter ended June 30, 2025) and an updated corporate presentation, both attached as Exhibits 99.1 and 99.2. Because the company explicitly states these items are "furnished" and not "filed," the disclosures carry the narrower legal treatment typical of routine operational updates. The 8-K provides no earnings, revenue, or cash-flow figures, so material financial analysis cannot be performed from this filing alone.

Corporate Governance Expert

TL;DR: Governance disclosure is standard: furnished materials and investor presentation posted; no governance changes disclosed.

The report confirms availability of investor-facing materials and reiterates the legal status of those materials as furnished rather than filed, limiting incorporation by reference. There is no mention of officer changes, board actions, securities issuances, or other governance events. For governance or material-event monitoring, stakeholders must review the attached exhibits themselves since substantive data are not included in the 8-K text.

0001671858false00016718582025-08-132025-08-130001671858dei:FormerAddressMember2025-08-132025-08-13

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

August 13, 2025

Date of Report (Date of earliest event reported)

ARS Pharmaceuticals, Inc.

(Exact name of registrant as specified in its charter)

Delaware		001-39756		81-1489190
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification No.)

11682 El Camino Real, Suite 300 San Diego, California		92130
(Address of principal executive offices)		(Zip Code)

Registrant’s telephone number, including area code: (858) 771-9307

11682 El Camino Real, Suite 120

San Diego, California 92130

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, $0.0001 par value per share		SPRY		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b–2 of the Securities Exchange Act of 1934 (§ 240.12b–2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02 Results of Operations and Financial Condition.

On August 13, 2025, ARS Pharmaceuticals, Inc. (the “Company”) announced its financial results for the quarter ended June 30, 2025 in the press release attached hereto as Exhibit 99.1 and incorporated herein by reference.

The information in this Item 2.02 of this Current Report on 8-K, including Exhibit 99.1, is furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or subject to the liabilities of that, or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference into any filing under the Exchange Act or the Securities Act of 1933 (the “Securities Act”), whether made before or after today’s date, regardless of any general incorporation language in such filing, except as shall be expressly set forth by specific references in such filing.

Item 7.01 Regulation FD Disclosure.

On August 13, 2025, the Company updated its corporate presentation for use with investors, analysts and others. The revised presentation is available through the Company’s website, and a copy of the presentation is attached as Exhibit 99.2 to this Current Report on Form 8-K.

The information in this Item 7.01 of this Current Report on 8-K, including Exhibit 99.2, is furnished and shall not be deemed “filed” for purposes of Section 18 of the Exchange Act, or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference into any filing under the Exchange Act or the Securities Act, whether made before or after today’s date, regardless of any general incorporation language in such filing, except as shall be expressly set forth by specific references in such filing.

Item 9.01 Financial Statements and Exhibits.

(d)

Exhibit Number		Description
99.1		Press Release dated August 13, 2025
99.2		Company Presentation dated August 13, 2025
104		Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

		ARS PHARMACEUTICALS, INC.
Date: August 13, 2025		By:	/s/ Richard Lowenthal, M.S., MSEL
			Richard Lowenthal, M.S., MSEL
			President and Chief Executive Officer
			(Principal Executive Officer)

FAQ

What did ARS Pharmaceuticals (SPRY) disclose in this 8-K?

The company furnished a press release with its financial results for the quarter ended June 30, 2025 (Exhibit 99.1) and an updated investor presentation (Exhibit 99.2).

Are the press release and presentation in the 8-K "filed" with the SEC?

No. The 8-K states the press release and presentation are furnished and shall not be deemed "filed" for purposes of the Exchange Act or incorporated by reference into other filings.

Where can I find the updated corporate presentation mentioned in the 8-K?

The 8-K says the revised presentation is available through the company's website and is attached as Exhibit 99.2 to the report.

What exhibits were included with this Form 8-K for ARS Pharmaceuticals?

Exhibit 99.1 is the press release, Exhibit 99.2 is the company presentation, and Exhibit 104 is the Cover Page Interactive Data File.

Is ARS Pharmaceuticals considered an emerging growth company in this filing?

Yes. The 8-K indicates the registrant is an emerging growth company under SEC rules.